The Operating Theatre Journal - Journal - Page 39
Discovering the the Operating Theatre Journal online @ www.otjonline.com
FDA Clears CorNeat EverPatch, World’s First Non-degradable,
Synthetic Tissue Substitute for Ophthalmic Surgery
CorNeat Vision’s EverPatch Utilizes EverMatrix™, A Novel Material Technology Able to Integrate with Surrounding Tissue
CorNeat Vision’s EverPatch, a synthetic
tissue substitute, has been granted
510(k) clearance by the US Food & Drug
Administration (FDA). The CorNeat
EverPatch is the first synthetic, nondegradable tissue-integrating matrix for
use in ophthalmic surgeries. It is composed
of a non-woven, polymer matrix which
integrates with surrounding tissue and is
intended to reinforce the sclera and aid
the physical reconstruction of the ocular
surface. This groundbreaking synthetic
tissue substitute is designed to address the
critical needs of ocular surgeons, providing
a sterile and non-degradable solution for
patients worldwide.
The CorNeat EverPatch is poised to displace
the use of donor and processed tissue,
commonly utilized in ocular surgeries but
posing the risk of disease transmission.
Dr. Gilad Litvin, CorNeat Vision’s Chief
Medical Officer and Co-Founder stated:
“The ideal graft material should be longlasting, sterile, immunologically inactive,
cosmetically acceptable, and readily
available. The CorNeat EverPatch was
designed with these goals in mind. Our
novel ophthalmic patch is significantly
thinner than processed patch tissue,
provides better handling as it does not
‘cheesewire’ when sutured, and has holes
that allow for accurate positioning and
anchoring. These holes also facilitate direct
conjunctival adhesion to the sclera thus
supporting its bio-integration. Thus far, we
have received extremely positive feedback
from surgeons and are excited for U.S.
surgeons to have this tool available.”
Left – CorNeat EverPatch; right – CorNeat EverPatch implanted under the conjunctiva, 9
months post implantation
Almog Aley-Raz, CorNeat Vision’s CEO and
VP R&D responded to the news:
“We are extremely excited to introduce
the CorNeat EverPatch to the U.S. market.
It is the first device that leverages the
EverMatrix™, our core tissue-integrating
material platform technology, originally
developed for our corneal prosthesis
program.
EverMatrix™ presents a significant business
opportunity as it is the only synthetic
non-degradable patch material in ocular
surgery. This biocompatible material has
the potential for wider use in soft tissue
reinforcement, biomechanical integration
of implants with surrounding tissue,
fabrication of membranes, and concealment
of implants and sensors. I cannot
overemphasize the potential impact of this
technology on human health.
Find out more 02921 680068 • e-mail admin@lawrand.com
Issue 393
This recent FDA clearance of our first device
for ophthalmic use advances us toward our
ultimate goal of promoting human health and
equality.”
The CorNeat EverPatch will be launched
initially in leading ophthalmic centers in the
U.S. in Q3 2023, expanding nationwide later
in the year.
Click HERE to learn more:
https://www.corneat.com/
SOURCE CorNeat Vision
THE
June
2023
39